Observation

BigBear.ai Achieves ‘Awardable’ Status on DoD’s Tradewinds Procurement Platform with 5 AI Solutions

Retrieved on: 
Monday, April 29, 2024
Technology, Defense, Government Technology, Military, Other Defense, Contracts, Retail, Consulting, Transportation, Professional Services, Travel, Security, Satellite, Nanotechnology, Air, Transport, Supply Chain Management, Software, Internet, Aerospace, Electronic Design Automation, Manufacturing, Logistics, Data Management, Observation, Trade winds, BBAI, AI, Sensor, Artificial intelligence, Intelligence, Digital, Acquisition, Data collection, Government, Marketplace

The DoD’s Tradewinds program acts as a central hub to streamline the adoption of cutting-edge artificial intelligence (AI) capabilities.

Key Points: 
  • The DoD’s Tradewinds program acts as a central hub to streamline the adoption of cutting-edge artificial intelligence (AI) capabilities.
  • This program serves as a uniquely efficient contracting vehicle, bridging the procurement gap between the DoD and industry partners like BigBear.ai.
  • With these solutions now available on the Tradewinds marketplace, they are considered post-competition, and DoD users are now able to satisfy standard competition requirements in government contracting.
  • BigBear.ai’s solutions now available on Tradewinds include:
    ConductorOS: BigBear.ai’s data and AI orchestration platform, ConductorOS operationalizes AI at the edge to accelerate decision-making for the operator, while supporting the integration of 3rd party AI/ML models.

Global $4.93 Bn Neonatal Intensive Care Market Trends, Competitive Analysis and Forecasts, 2018-2023 & 2024-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 29, 2024
Medical Devices, Health, Consumer, Hospitals, Baby, Maternity, General Health, Conditional sentence, Hypothermia, Mortality, NICU, Humidity, Infant, Risk, Hospital, Page, Death, Jaundice, SWOT analysis, Medicine, Research, Light, Growth, Heart rate, Observation, Application, Incidence, Patient, Developed country, European Journal, White lung, Pediatrics, Temperature, Government, RDS, Prevalence, Disease, Dietary supplement

North America dominated the global neonatal intensive care market in 2023, followed by Europe.

Key Points: 
  • North America dominated the global neonatal intensive care market in 2023, followed by Europe.
  • Neonatal monitoring devices such as cardiac monitors are used in neonatal intensive care units for continuous monitoring of neonates.
  • The neonatal & pediatric hospital facilities dominate the global neonatal intensive care market because of their specialized information, dedicated infrastructure, and comprehensive services.
  • The increasing number of maternity hospitals offering neonatal intensive care services worldwide increases the popularity of this segment.

New Research Reveals What Each Country Has That's Bigger Than any Other Country, Including Some Weird Things

Retrieved on: 
Tuesday, April 30, 2024
Observation, Guinness World Records, Research

CLAYMONT, Del., April 30, 2024 /PRNewswire/ -- Every country in the world presumably has something that's gigantic when compared to the other countries. To gain some insight, Size Graf has performed their own research using Guinness World Records to find out what each country has that's bigger than the other countries. The research findings revealed there are several weird items among the most giant things worldwide.

Key Points: 
  • The results show that some of the relatively hugest things in different countries are weird and unexpected.
  • CLAYMONT, Del., April 30, 2024 /PRNewswire/ -- Every country in the world presumably has something that's gigantic when compared to the other countries.
  • To gain some insight, Size Graf has performed their own research using Guinness World Records to find out what each country has that's bigger than the other countries.
  • The research findings revealed there are several weird items among the most giant things worldwide.

National Infertility Awareness Week: ARC Fertility Supports Family Building Act, Advocates Alongside RESOLVE and American Society for Reproductive Medicine

Retrieved on: 
Monday, April 22, 2024
LGBTQ+, Professional Services, Family, Consumer, Hospitals, Advocacy Group Opinion, Health Insurance, Parenting, Baby, Maternity, Insurance, Congressional News, Views, Health, Public Policy, Government, Congress, Fertility, NIAW, ARC, Infertility, MD, Member of Congress, Partnership, Senate, FACS, IVF, FRCSC, Observation, Reproductive medicine, Patient, Legislation, Society, Access, ASRM, FACOG, Organization

ARC® Fertility , a highly experienced national provider of innovative fertility and family-forming benefits for self-insured employers and their employees, proudly recognizes National Infertility Awareness Week ® (NIAW), an event founded by RESOLVE in 1989.

Key Points: 
  • ARC® Fertility , a highly experienced national provider of innovative fertility and family-forming benefits for self-insured employers and their employees, proudly recognizes National Infertility Awareness Week ® (NIAW), an event founded by RESOLVE in 1989.
  • “During this significant observation, ARC Fertility also reaffirms its commitment to supporting legislative measures that enhance access to family-building services,” says David Adamson, MD, FRCSC, FACOG, FACS, Founder and CEO, ARC Fertility.
  • “We proudly announce our support for the Access to Family Building Act sponsored by U.S.
  • ARC Fertility has a longstanding history of collaboration with RESOLVE and other advocacy organizations in the field of reproductive health.

Media Alert: BrainChip Highlights the 2nd Generation Akida at tinyML Summit 2024

Retrieved on: 
Thursday, April 18, 2024
Software, Hardware, Robotics, Data Management, IOT (Internet of Things), Technology, Artificial Intelligence, Semiconductor, Satellite, Engineering, Aerospace, Manufacturing, Ecosystem, OTCQX, Internet of things, AI, Exhibition, ASX, Observation, ADR, Classification, San Francisco International Airport, Neuromorphic engineering, Head, BrainChip, Video game

As part of its exhibition, BrainChip will showcase their latest iteration of Akida technology that enables more advanced, more capable, and more accurate AI.

Key Points: 
  • As part of its exhibition, BrainChip will showcase their latest iteration of Akida technology that enables more advanced, more capable, and more accurate AI.
  • "BrainChip leads the market in Neuromorphic IP, which allows our customers to build very low energy AI devices at the edge.
  • BrainChip’s neural processor, Akida IP is an event-based technology that is inherently lower power when compared to conventional neural network accelerators.
  • Those interested in meeting with the BrainChip team at the tinyML Summit 2024 Open Expo on Monday, April 22, from 3-7 p.m. PDT are invited to register for free at tinyML Summit 2024 - Open Expo Registration

Ferring Adds Three New Studies to Non-Muscle Invasive Bladder Cancer Clinical Trial Program With ADSTILADRIN® (nadofaragene firadenovec-vncg)

Retrieved on: 
Tuesday, April 16, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Real-World Evidence, FDA, RWE, Investment, Safety, Food, Pembrolizumab, Immunotherapy, Health care, ABLE, Carcinoma in situ, Physician, Research, BCG, Docetaxel, Observation, CIS, Senior, Patient, Ferring Pharmaceuticals, NMIBC, Bacillus, Clinical trial, Urinary bladder, Bladder cancer, Ageing, Pharmaceutical industry

Ferring Pharmaceuticals today announced start up of new studies in the United States (U.S.) for three new ADSTILADRIN in BLadder cancEr (ABLE) clinical trials in patients with non-muscle invasive bladder cancer (NMIBC) with plans to expand select clinical trials outside of the U.S. later this year.

Key Points: 
  • Ferring Pharmaceuticals today announced start up of new studies in the United States (U.S.) for three new ADSTILADRIN in BLadder cancEr (ABLE) clinical trials in patients with non-muscle invasive bladder cancer (NMIBC) with plans to expand select clinical trials outside of the U.S. later this year.
  • ABLE-32: A Phase 3b randomized, controlled clinical study to evaluate the safety and efficacy of ADSTILADRIN versus observation in patients with intermediate-risk NMIBC.
  • The ABLE-22, ABLE-32 and ABLE-42 clinical trials announced today are yet another milestone for this comprehensive research program.
  • Healthcare providers in the U.S. can learn more about the ADSTILADRIN clinical trial program by calling 1-888-FERRING (888-337-7464) and selecting option number one or emailing [email protected] .

Proposed Changes to BenevolentAI’s Board Composition

Retrieved on: 
Monday, April 15, 2024
Technology, Research, Finance, Health Technology, Professional Services, Biotechnology, Health, Science, Artificial Intelligence, Annual general meeting, CFO, Cure, Investment, AI, Neo-noir, Partnership, Business, Growth, Corporate development, GI Partners, BAI, Intellectual property, Drug discovery, LifeArc, AIM, Trust, Amphisbaena, Nomination, Therapy, Euronext Amsterdam, Abcam, P74, Research and development, Trustee, Artificial intelligence, Observation, Chairperson, Digital, Recipharm, Partner, Government, Sale, The Carlyle Group, Business development, Accel-KKR, Senior, Acquisition, F2G, Risk, Audit, AGM, Oxford Nanopore Technologies, Management

Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.

Key Points: 
  • Dr. Joerg Moeller, Chief Executive Officer, Jean Raby, Senior Independent Director, Prof. Sir Nigel Shadbolt and Dr. John Orloff, both Non-Executive Directors, will all continue in their respective positions on the Board of BenevolentAI.
  • Subject to their appointment at the AGM, it is proposed that Mr. Allen acts as Chair and Mr. Mulvany acts as Deputy Chair of the Board.
  • Together with the rest of the Board, they will support Chief Executive Dr. Jeorg Moeller and his team on implementing the Company’s strategy.
  • He has extensive Board experience in public and private companies and is currently Chairman of Bioventix plc, where he was appointed in 2004 and a Board Trustee of LifeArc, a leading UK medical research charity.

OncoNano Medicine Presents Preclinical Data for ON-BOARD™ IL-12 Program at AACR Annual Meeting 2024

Retrieved on: 
Wednesday, April 10, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Mouse, Safety, IL-12, Gamma ray, Animal, Research and development, Plasma, Development, Observation, Therapy, Patient, Liver, Therapeutic index, AACR, NK

Despite its potent pleiotropic and well-established anti-cancer effects, the clinical application of IL-12 has been hindered by significant adverse toxicities.

Key Points: 
  • Despite its potent pleiotropic and well-established anti-cancer effects, the clinical application of IL-12 has been hindered by significant adverse toxicities.
  • OncoNano developed ON-BOARD™, an ultra-pH sensitive nanoparticle platform, to shield payloads from systemic exposure and target solid tumors by responding to the highly acidic tumor microenvironment.
  • Findings also reveal that ONM-412 illustrates favorable stability and pH-responsive IL-12 bioactivity in vitro,” said Tian Zhao, Ph.D., Vice President of Research and Development for OncoNano Medicine.
  • Link to the poster may be found on the OncoNano Medicine website at: News - OncoNano Medicine .

GPT-4 Powered All-In-One Smart Bird Feeder by RobinsNote to Launch on Kickstarter

Retrieved on: 
Tuesday, April 23, 2024
Intelligence, Observation, Bird feeder, Fruit, Seed, Bird, Kickstarter, Knowledge, AI, Animal husbandry

HONG KONG, April 23, 2024 /PRNewswire/ -- RobinsNote is set to launch its OpenAI powered (GPT-4) Smart Bird feeder, coming 1st June on Kickstarter.

Key Points: 
  • HONG KONG, April 23, 2024 /PRNewswire/ -- RobinsNote is set to launch its OpenAI powered (GPT-4) Smart Bird feeder, coming 1st June on Kickstarter.
  • The new Bird Feeder by RobinsNote offers more than just the traditional observing experience.
  • OpenAI's GPT-4 Technology: The bird feeder by RobinsNote drives power from the intelligence of OpenAI's GPT-4 and can identify bird species.
  • Embrace the beauty of bird watching like never before with RobinsNote's latest breakthrough in smart Bird feeder technology.

Zayed Sustainability Prize's Beyond2020 Initiative Deploys Life-saving Digital Mammograms in Costa Rica

Retrieved on: 
Tuesday, April 23, 2024
Health equity, AI, Health, Survival, Artificial intelligence, SME, Water, Development, Observation, Patient, Medicine, Ministry, Anomaly, Diagnosis, BNP Paribas, Quality of life, MSW, Breast cancer, Drug

ABU DHABI, UAE, April 23, 2024 /PRNewswire/ -- Beyond2020, the flagship initiative launched by the Zayed Sustainability Prize, the UAE's pioneering award for sustainability and humanitarianism, today announced the deployment of AI-powered mammography services across Costa Rica to support the early detection and treatment of breast cancer for women living in underprivileged communities.

Key Points: 
  • A cutting-edge mobile unit has also been deployed, reaching underserved areas across Costa Rica where access to healthcare may be limited.
  • Rawdha Alotaiba, Ambassador, UAE Embassy in Costa Rica, said: "Further strengthening the bilateral relations between UAE and Costa Rica, Beyond2020 and its partners are pleased to introduce a project that will enhance the prosperity and wellbeing of 8,000 women annually in Costa Rica, particularly women in remote and underprivileged communities.
  • Cindy Quesada Hernández, Ministry of the Status of Women (MSW), Costa Rica, stated: "Promoting a preventive culture and self-care contributes to women in Costa Rica leading healthier lives.
  • After winning the Zayed Sustainability Prize in 2022, Mamotest expanded operations of its state-of-the-art diagnostic centres beyond Argentina to Mexico, Costa Rica, Brazil and Spain.